Mir-24-3p downregulation contributes to VP16–DDP resistance in small-cell lung cancer by targeting ATG4A

Although the combination of etoposide (VP16) and cisplatin (DDP) is widely used as a first-line treatment for advanced-stage small-cell lung cancer (SCLC), chemoresistance limits its clinical use. Abnormalities of autophagy are associated with tumor chemoresistance. The present study found that miR-...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Banzhou, Chen, Yitian, Song, Haizhu, Xu, Yichen, Wang, Rui, Chen, Longbang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381597/
https://www.ncbi.nlm.nih.gov/pubmed/25426560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381597/
https://www.ncbi.nlm.nih.gov/pubmed/25426560

Ejemplares similares